Calithera Biosciences Inc. (CALA) Sees Large Volume Increase
Shares of Calithera Biosciences Inc. (NASDAQ:CALA) saw an uptick in trading volume on Friday . 551,192 shares traded hands during trading, an increase of 86% from the previous session’s volume of 295,608 shares.The stock last traded at $3.40 and had previously closed at $3.44.
Several brokerages have recently commented on CALA. JMP Securities reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $10.48.
The company’s market cap is $65.02 million. The stock has a 50-day moving average of $4.41 and a 200-day moving average of $5.30.
Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.05. Equities research analysts predict that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.